NCT01402336View on ClinicalTrials.gov

GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
InfertilityPolycystic Ovary Syndrome
Interventions
DRUG

GnRH antagonist (Cetrorelix)

In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation

DRUG

Conventional GnRH agonist (Triptorelin)

Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT01402336 - GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer | Biotech Hunter | Biotech Hunter